T1	CHEM 109 119	bortezomib
#1	AnnotatorNotes T1	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T2	CHEM 121 128	Velcade
#2	AnnotatorNotes T2	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T3	CHEM 132 144	lenalidomida
#3	AnnotatorNotes T3	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T4	CHEM 146 154	Revlimid
#4	AnnotatorNotes T4	C1135145; Revlimid; Organic Chemical · Pharmacologic Substance
T5	CHEM 159 171	dexametasona
#5	AnnotatorNotes T5	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T6	DISO 189 205	mieloma múltiple
#6	AnnotatorNotes T6	C0026764; Multiple Myeloma; Neoplastic Process
T7	PROC 213 226	diagnosticado
#7	AnnotatorNotes T7	C0011900; Diagnosis; Diagnostic Procedure
T8	PROC 245 255	trasplante
#8	AnnotatorNotes T8	C0040732; Transplantation; Therapeutic or Preventive Procedure
T9	PROC 278 335	Estudio multicéntrico, abierto, aleatorizado, en fase III
T10	CHEM 416 426	bortezomib
#9	AnnotatorNotes T10	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T11	CHEM 428 435	Velcade
#10	AnnotatorNotes T11	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T12	CHEM 439 451	lenalidomida
#11	AnnotatorNotes T12	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T13	CHEM 453 461	Revlimid
#12	AnnotatorNotes T13	C1135145; Revlimid; Organic Chemical · Pharmacologic Substance
T14	CHEM 466 478	dexametasona
#13	AnnotatorNotes T14	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T15	CHEM 488 498	bortezomib
#14	AnnotatorNotes T15	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T16	CHEM 500 512	lenalidomida
#15	AnnotatorNotes T16	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T17	CHEM 515 527	dexametasona
#16	AnnotatorNotes T17	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T18	DISO 545 561	mieloma múltiple
#17	AnnotatorNotes T18	C0026764; Multiple Myeloma; Neoplastic Process
T19	PROC 569 582	diagnosticado
#18	AnnotatorNotes T19	C0011900; Diagnosis; Diagnostic Procedure
T20	PROC 601 611	trasplante
#19	AnnotatorNotes T20	C0040732; Transplantation; Therapeutic or Preventive Procedure
T21	DISO 635 665	Mieloma de células plasmáticas
#20	AnnotatorNotes T21	C0026764; Multiple Myeloma; Neoplastic Process
T22	PROC 1199 1206	Tratado
#21	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	DISO 692 720	Mieloma múltiple sintomático
T24	PROC 784 795	diagnóstico
#22	AnnotatorNotes T24	C0011900; Diagnosis; Diagnostic Procedure
T25	PROC 828 857	tratamiento con quimioterapia
T26	DISO 925 951	enfermedades concomitantes
#23	AnnotatorNotes T26	C0243087; concomitant disease; Pathologic Function
T27	PROC 1024 1037	quimioterapia
#24	AnnotatorNotes T27	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T28	DISO 1074 1092	enfermedad medible
#25	AnnotatorNotes T28	C1513041; Measurable Disease; Disease or Syndrome
T29	DISO 1227 1243	mieloma múltiple
#26	AnnotatorNotes T29	C0026764; Multiple Myeloma; Neoplastic Process
T30	DISO 1244 1273	Mieloma múltiple asintomático
T31	DISO 1286 1298	enfermedades
#27	AnnotatorNotes T31	C0012634; Disease; Disease or Syndrome
T32	PROC 1385 1412	Valores de función orgánica
T33	DISO 1478 1495	Hipersensibilidad
#28	AnnotatorNotes T33	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T34	CHEM 1501 1511	medicación
#29	AnnotatorNotes T34	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T35	PROC 1608 1631	métodos anticonceptivos
#30	AnnotatorNotes T35	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T36	PROC 1712 1739	asesoramiento contraceptivo
T37	PROC 1057 1060	TCM
#31	AnnotatorNotes T37	C1504389; Stem cell transplant; Therapeutic or Preventive Procedure (?)
T38	CHEM 67 77	isatuximab
#32	AnnotatorNotes T38	C4330502; isatuximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T39	ANAT 646 665	células plasmáticas
#33	AnnotatorNotes T39	C0032112; Plasma Cells; Cell
T40	PROC 1123 1147	consentimiento informado
#34	AnnotatorNotes T40	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T41	CHEM 374 384	isatuximab
#35	AnnotatorNotes T41	C4330502; isatuximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T42	CHEM 79 88	SAR650984
#36	AnnotatorNotes T42	C2983777; SAR650984; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T43	CHEM 386 395	SAR650984
#37	AnnotatorNotes T43	C2983777; SAR650984; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T44	DISO 1301 1321	condiciones de salud
#38	AnnotatorNotes T44	C0683314; health status; Finding
T45	Date 13 17	2017
T46	LIVB 175 184	pacientes
#39	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	Neg_cue 227 229	no
T48	LIVB 531 540	pacientes
#40	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Neg_cue 583 585	no
T50	LIVB 770 779	Pacientes
#41	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Date 796 804	reciente
T52	Neg_cue 807 809	no
T53	Dose 861 872	dosis altas
#42	AnnotatorNotes T53	C0444956; High dose; Quantitative Concept
T54	Age 888 896	≥65 años
T55	Age 900 908	<65 años
T58	Dose 1041 1052	dosis altas
#43	AnnotatorNotes T58	C0444956; High dose; Quantitative Concept
T59	Spec_cue 1062 1073	Indicios de
T60	LIVB 1093 1102	Pacientes
#44	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Age 1179 1197	inferior a 18 años
T63	PHYS 1396 1412	función orgánica
#45	AnnotatorNotes T63	C1254358; Organ or Tissue Function; Organ or Tissue Function
T64	PHYS 1524 1532	Embarazo
#46	AnnotatorNotes T64	C0032961; Pregnancy; Organism Function
T65	PHYS 1534 1551	lactancia materna
#47	AnnotatorNotes T65	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T66	LIVB 1554 1574	mujer en edad fértil
#48	AnnotatorNotes T66	C4324275; Woman of childbearing potential; Population Group
T67	Age 1563 1574	edad fértil
T69	Neg_cue 1579 1581	no
T70	Neg_cue 1679 1681	no
T56	LIVB 1650 1674	participantes masculinos
#49	AnnotatorNotes T56	C4554048; Study Participant; Population Group + C0025266; Male population group; Population Group
T57	Date 1332 1340	en curso
T62	PROC 1435 1451	Estado funcional
#50	AnnotatorNotes T62	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T68	PROC 1453 1455	EF
#51	AnnotatorNotes T68	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T71	LIVB 1544 1551	materna
#52	AnnotatorNotes T71	C0026591; Mother (person); Family Group
A1	Assertion T8 Negated
A2	Assertion T20 Negated
A3	Assertion T25 Negated
A4	Assertion T53 Negated
A5	Assertion T28 Speculated
A6	Population_data T66 Age
A7	Assertion T35 Negated
A8	Assertion T36 Negated
A9	Status T22 History_of
A10	Status T44 History_of
A11	Status T31 History_of
A12	Status T33 History_of
#53	AnnotatorNotes T9	C1096776; Multicenter Study; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity
#54	AnnotatorNotes T30	C0026764; Multiple Myeloma; Neoplastic Process + C0231221; Asymptomatic (finding); Finding
#55	AnnotatorNotes T36	C5551525; Contraceptive counseling; Health Care Activity 
#56	AnnotatorNotes T51	C0332185; Recent; Temporal Concept
T72	Neg_cue 1417 1419	no
T73	Quantifier_or_Qualifier 1425 1434	adecuados
A13	Assertion T73 Negated
T74	Spec_cue 956 969	probablemente
T75	Observation 970 997	influyan de manera negativa
A14	Assertion T75 Negated
R1	Negation Arg1:T72 Arg2:T73	
T76	Observation 46 63	Beneficio clínico
#57	AnnotatorNotes T76	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R2	Causes Arg1:T38 Arg2:T76	
R3	Causes Arg1:T42 Arg2:T76	
R4	Combined_with Arg1:T38 Arg2:T1	
R5	Combined_with Arg1:T42 Arg2:T1	
R6	Combined_with Arg1:T38 Arg2:T2	
R7	Combined_with Arg1:T42 Arg2:T2	
R8	Combined_with Arg1:T1 Arg2:T3	
R9	Combined_with Arg1:T2 Arg2:T3	
R10	Combined_with Arg1:T1 Arg2:T4	
R11	Combined_with Arg1:T2 Arg2:T4	
R12	Combined_with Arg1:T3 Arg2:T5	
R13	Combined_with Arg1:T4 Arg2:T5	
R14	Experiences Arg1:T46 Arg2:T76	
R15	Experiences Arg1:T46 Arg2:T38	
R16	Experiences Arg1:T46 Arg2:T42	
R17	Experiences Arg1:T46 Arg2:T6	
R18	Experiences Arg1:T46 Arg2:T8	
R19	Negation Arg1:T47 Arg2:T8	
T77	Quantifier_or_Qualifier 206 226	recién diagnosticado
#58	AnnotatorNotes T77	C1518321; Newly Diagnosed; Qualitative Concept
R20	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T77	
T78	Quantifier_or_Qualifier 562 582	recién diagnosticado
#59	AnnotatorNotes T78	C1518321; Newly Diagnosed; Qualitative Concept
R21	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T78	
T79	Observation 353 370	beneficio clínico
#60	AnnotatorNotes T79	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R22	Causes Arg1:T41 Arg2:T79	
R23	Causes Arg1:T43 Arg2:T79	
R24	Combined_with Arg1:T41 Arg2:T10	
R25	Combined_with Arg1:T43 Arg2:T10	
R26	Combined_with Arg1:T43 Arg2:T11	
R27	Combined_with Arg1:T41 Arg2:T11	
R28	Combined_with Arg1:T10 Arg2:T12	
R29	Combined_with Arg1:T10 Arg2:T13	
R30	Combined_with Arg1:T11 Arg2:T12	
R31	Combined_with Arg1:T11 Arg2:T13	
R32	Combined_with Arg1:T13 Arg2:T14	
R33	Combined_with Arg1:T12 Arg2:T14	
R34	Experiences Arg1:T48 Arg2:T79	
R35	Experiences Arg1:T48 Arg2:T41	
R36	Experiences Arg1:T48 Arg2:T43	
R37	Experiences Arg1:T48 Arg2:T15	
R38	Combined_with Arg1:T15 Arg2:T16	
R39	Combined_with Arg1:T16 Arg2:T17	
R40	Experiences Arg1:T48 Arg2:T18	
R41	Experiences Arg1:T48 Arg2:T20	
R42	Negation Arg1:T49 Arg2:T20	
R43	Location_of Arg1:T39 Arg2:T21	
R44	Experiences Arg1:T50 Arg2:T25	
R45	Negation Arg1:T52 Arg2:T25	
#61	AnnotatorNotes T25	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
R46	Negation Arg1:T52 Arg2:T53	
R47	Has_Dose_or_Strength Arg1:T25 Arg2:T53	
R48	Overlap Arg1:T24 Arg2:T51	
R49	Has_Age Arg1:T50 Arg2:T54	
R50	Has_Age Arg1:T50 Arg2:T55	
R51	Experiences Arg1:T50 Arg2:T26	
T80	Quantifier_or_Qualifier 913 924	importantes
#62	AnnotatorNotes T80	C3898777; Important; Qualitative Concept
R52	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T80	
R53	Speculation Arg1:T74 Arg2:T75	
R54	Before Arg1:T26 Arg2:T75	
A15	Assertion T27 Negated
R55	Negation Arg1:T52 Arg2:T27	
R56	Has_Dose_or_Strength Arg1:T27 Arg2:T58	
A16	Assertion T58 Negated
R57	Experiences Arg1:T50 Arg2:T27	
R58	Experiences Arg1:T50 Arg2:T37	
A17	Assertion T37 Negated
R59	Negation Arg1:T52 Arg2:T37	
R60	Combined_with Arg1:T27 Arg2:T37	
R61	Speculation Arg1:T59 Arg2:T28	
R62	Overlap Arg1:T44 Arg2:T57	
R63	Overlap Arg1:T31 Arg2:T57	
R64	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T73	
T81	CONC 750 768	criterios del IMWG
#63	AnnotatorNotes T81	C5204711; International Myeloma Working Group Standard Response Criteria; Intellectual Product (?)
#64	AnnotatorNotes T73	C0205411; Adequate; Qualitative Concept
T82	Result_or_Value 1465 1477	superior a 2
T83	CONC 1460 1464	ECOG
#65	AnnotatorNotes T83	C1520224; ECOG performance status; Intellectual Product
R65	Has_Result_or_Value Arg1:T83 Arg2:T82	
R66	Used_for Arg1:T83 Arg2:T62	
R67	Used_for Arg1:T83 Arg2:T68	
R68	Causes Arg1:T34 Arg2:T33	
R69	Experiences Arg1:T71 Arg2:T65	
R70	Has_Age Arg1:T66 Arg2:T67	
T84	Observation 1587 1596	dispuesta
#66	AnnotatorNotes T84	C0600109; Willing; Finding (?)
R71	Negation Arg1:T69 Arg2:T84	
R72	Overlap Arg1:T84 Arg2:T35	
R73	Experiences Arg1:T66 Arg2:T84	
R74	Experiences Arg1:T66 Arg2:T35	
R75	Negation Arg1:T69 Arg2:T35	
A18	Assertion T84 Negated
R76	Experiences Arg1:T56 Arg2:T36	
R77	Negation Arg1:T70 Arg2:T36	
#67	AnnotatorNotes T57	C0521116; Current (present time); Temporal Concept
A19	Experiencer T46 Patient
A20	Experiencer T48 Patient
A21	Experiencer T50 Patient
A22	Experiencer T60 Patient
A23	Experiencer T71 Patient
A24	Experiencer T66 Patient
A25	Experiencer T56 Patient
